Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843343 | 1.00 | CCR3 (0.64) | CCR3ACHEHTR2AGBA1KDM4E | |
| SCHEMBL5069409 | 1.00 | CCR3 (0.64) | CCR3ACHEHTR2AGBA1KDM4E | |
| SCHEMBL1918964 | 0.90 | CCR3 (0.73) | CCR3ACHEHTR2AKDM4ECYP1A2 | |
| SCHEMBL9682520 | 0.86 | GBA1 (0.62) | CCR3ACHEGBA1CYP2D6SLC6A3 | |
| SCHEMBL6172031 | 0.84 | CCR3 (0.64) | CCR3ACHESLC6A3 | |
| SCHEMBL843329 | 0.84 | CCR3 (0.64) | CCR3ACHESLC6A3 | |
| SCHEMBL11023730 | 0.84 | CCR3 (0.64) | CCR3ACHESLC6A3 | |
| SCHEMBL5779205 | 0.84 | CCR3 (0.64) | CCR3ACHESLC6A3 | |
| SCHEMBL8545766 | 0.83 | CYP2D6 (0.68) | CCR3ACHECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5968994 | 0.83 | CYP2D6 (0.68) | CCR3ACHECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103626687-A | Synthetic method for (3R)-1-[(R)-1-phenethyl]-3-hydroxymethyl pyrrolidine | CHEMFUTURE PHARMATECH JIANGSU LTD | 2014-03-12 | — | — | CN | disclosed |
| CN-103626687-A | Synthetic method for (3R)-1-[(R)-1-phenethyl]-3-hydroxymethyl pyrrolidine | CHEMFUTURE PHARMATECH JIANGSU LTD | 2014-03-12 | — | — | CN | disclosed |
| CN-1093861-C | 1-methylcarbapenem derivatives | SANKYO CO (JP) | 2002-11-06 | — | — | CN | disclosed |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | CCR3 3204/4885ACHE 126/4885HTR2A 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.